Indegene Continues Strong Momentum with 17% YoY Revenue Growth, Expands Capabilities Through Two Strategic Acquisitions

Indegene, the tech-native, life sciences specialist, announced its financial results for the quarter ended September 30, 2025. The company achieved a revenue of INR 8,042 million, reflecting 17% growth YoY & 5.7% growth QoQ. Indegene also maintained a strong profitability profile, with an adjusted EBITDA margin of 18.2% and a PAT margin of 12.7%. The company announced two acquisitions: BioPharm, a US-based specialized marketing services agency with deep expertise in omnichannel strategy, end-to-end media journey, and hyper-targeted HCP engagement solutions, and WARN & CO., a UK-based transformation consulting firm with a proven track record in helping global organizations design and transition to new operating models, systems, and ways of working.